ClinicalTrials.gg
RecruitingNCT07134387BronQ FamilyUpdated Nov 21, 2025

Long-Term Burden of BPD and Health-Related Quality of Life (BronQ Family)

An observational study in Bronchopulmonary Dysplasia (BPD), Chronic Lung Disease of Newborn and HRQOL (Health Related Quality Of Life), sponsored by Global Foundation for the Care of Newborn Infants. Recruiting at 1 site in Germany. Open to participants aged 0 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Global Foundation for the Care of Newborn Infants · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
480
Ages
0 Years to 18 Years
Sex
All
01

Study summary

The objective of this study is to examine the long-term impact of having a child with Bronchopulmonary Dysplasia (BPD) on the parents and caregivers from the time of diagnosis through adulthood. The primary focus will be on parents and caregivers of children until the age of 18 (\< 18) years who were diagnosed with BPD as newborns. Data will be collected through an online questionnaire in France, Germany, Italy, the Netherlands, Spain, the United Kingdom (including Northern Ireland), and the United States. It will ask about inclusion and exclusion criteria, background information (caregiver, child, and family situation), the child's medical situation, parental health-related quality of life (HRQoL), health literacy, feelings, support structures, and economic burden of the family.

Read the detailed description

The study will be designed as an observational, cross-sectional survey with a comparison group using a self-administered, web-based questionnaire for retrospective data collection. The study will use a multi-lingual online survey collecting data from parents in France, Germany, Italy, the Netherlands, Spain, the United Kingdom (including Northern Ireland), and the United States. Following a participatory research approach, the study will be carried out in close collaboration with representatives of national and international parent organizations, affected parents and/or former patients, professional healthcare societies, healthcare professionals as well as health researchers in the form of a Project Expert Group (PEG). It includes medical experts in BPD and neonatal/pediatric care, parent representatives, and, if applicable, parents of children affected by BPD during the neonatal period and/or affected patients from the countries of interest. The PEG will be complemented by the External Scientific Advisory Board (ESAB), which comprises n=4 members, including researchers specializing in HRQoL and/or pediatric respiratory outcomes research, including BPD. The PEG and ESAB will be engaged in all stages of the research project through regular online meetings. The ESAB contributes mainly to the study design and conception, questionnaire development, data analysis and interpretation, and will support the development of scientific publications. The remaining members of the PEG are involved in reviewing all final materials generated from the project and support the recruitment of study participants, as well as the dissemination of findings within their professional networks.

After comprehensive literature research and exchange with the study experts, the questionnaire will be drafted considering the already existing PedsQL Family Impact Module (FIM) (15) to assess parental HRQoL. In addition to socio-demographic information and inclusion/exclusion criteria, the questionnaire includes items evaluating various dimensions of parental HRQoL, health literacy and support structures. Furthermore, questions assessing the child's medical situation, treatment and eventual co-morbidities during the newborn period as well as at the time of the current survey will be added. Ultimately, questions addressing the financial burden of medical costs will be considered to assess the personal impact as well as the impact on the healthcare system in the respective countries. A unified questionnaire will be utilized for all participants, irrespective of their group assignment. Participants will be assigned to the BPD or comparison group retrospectively, based on their answers defining the BPD-status. To enhance comprehension, the questionnaire avoids using the term "BPD" wherever feasible and instead employs a more general reference to lung problems.

The questionnaire draft will be developed in close collaboration with the ESAB and reviewed by the PEG. After implementing necessary changes, the updated version will be shared again with the expert groups for final review. In addition, a pretest with up to 10 participants resembling the target group will be performed to elaborate on understanding, relevance and completeness as well as to elucidate other relevant topics that have not yet been covered and still need to be included.

After a potential adaptation based on data and information of the pre-testing, the questionnaire will be translated in the respective country languages with the PEG reviewing the translations. The translated questionnaire versions will be transferred into the online survey software SurveyMonkey® and will be distributed via the PEG/ESAB, GFCNI's network, GFCNI's newsletter and social media channels via an access link.

GFCNI received a research grant from Chiesi in support of this independent study.

02

Conditions studied

  • Bronchopulmonary Dysplasia (BPD)
  • Chronic Lung Disease of Newborn
  • HRQOL (Health Related Quality Of Life)

Keywords

  • Parental Quality of life
  • QoL
  • Health-related quality of life
  • HRQoL
  • Caregiver burden
  • Parental well-being
  • Family
  • Bronchopulmonary Dysplasia (BPD)
  • Chronic Lung Disease (CLD)
  • Chronic Lung Diseaseof Newborn
  • Respiratory Morbidity
  • Long-term outcomes
  • Parents
  • Caregivers
  • Infants
  • Newborn
  • Children
  • Preterm
  • Prematurity
  • NICU
  • Intensive Care
  • Neonatal
  • Survey
  • Questionnaire
  • Multinational study
  • retrospective data collection
  • participatory research
  • Patient-reported outcomes
  • PROs
  • Patient-reported outcome measures
  • PROMs
03

In context

Bronchopulmonary Dysplasia

363 studies on the registry are indexed under Bronchopulmonary Dysplasia; 85 are open to participants now.

This study's planned enrollment of 480 is above the median of 150 across 100 observational studies indexed under Bronchopulmonary Dysplasia.

Browse Bronchopulmonary Dysplasia studies →

Lead sponsor

Global Foundation for the Care of Newborn Infants is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of parents and caregivers of preterm-born children under 18 years old who have already been discharged from their initial hospital stay. Participants will be recruited from multiple countries, including France, Germany, Italy, the Netherlands, Spain, the United Kingdom/Northern Ireland, and the United States. They will be assigned to the BPD or comparison group retrospectively, based on their answers defining the BPD-status.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

BPD-group:

  • Being a parent or primary caregiver of a child until the age of 18 years (0 to under 18 years),

    • who was born preterm (before 37 weeks of gestation),
    • who has been discharged from their initial hospital stay after birth,
    • who suffered from BPD in the newborn period and
    • who was born or is currently living in the following countries: France, Germany, Italy, the Netherlands, Spain, the United Kingdom (including Northern Ireland) and the United States
  • providing sufficient proficiency in one of the languages of the questionnaire

Control group:

  • Being a parent or primary caregiver of a child until the age of 18 years (0 to under 18 years),

    • who was born preterm (before 37 weeks of gestation),
    • who has been discharged from their initial hospital stay after birth,
    • who did not suffer from BPD in the newborn period and
    • who was born or is currently living in the following countries: France, Germany, Italy, the Netherlands, Spain, the United Kingdom (including Northern Ireland) and the United States
  • providing sufficient proficiency in one of the languages of the questionnaire

Exclusion criteria

Exclusion Criteria:

BPD-group:

  • Other family members than parents/primary caregivers
  • Parents or primary caregivers

    • of a child older/equal than 18 years of age
    • of a child with BPD who has not been discharged yet
    • of a child without a BPD in the newborn period
    • with insufficient proficiency in one of the languages available in the questionnaire

Control group:

  • Other family members than parents/primary caregivers
  • Parents or primary caregivers

    • of children older/equal than 18 years of age
    • of a child born term
    • of a child without BPD who has not been discharged yet
    • with insufficient proficiency in one of the languages available in the questionnaire
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
480 participants (estimated)
Patient registry
No

Groups and cohorts

  • Parents or caregivers of children with (a history of) physician diagnosed BPD

    The primary population of this study consists of parents and caregivers of preterm born children (\< 37 weeks of gestation) under 18 years old who have been diagnosed with newborn-onset Bronchopulmonary Dysplasia (BPD). Furthermore, the child should have been discharged from their initial hospital stay after birth. Participants will be recruited from multiple countries, including France, Germany, Italy, the Netherlands, Spain, the United Kingdom (including Northern Ireland), and the United States.

    Other: N/A, no intervention, participation in survey

  • Parents or caregivers of preterm born children without chronic health conditions

    The control group consists of parents and caregivers of preterm born children (\< 37 weeks of gestation) under 18 years old who do not report a history of BPD. Furthermore, the child should have been discharged from their initial hospital stay after birth. They will as well be recruited from France, Germany, Italy, the Netherlands, Spain, the United Kingdom (including Northern Ireland), and the United States. If the final sample size permits, a post hoc filter will be applied to restrict analyses to the subgroup of very preterm (\< 32 weeks gestation) and/or very low birthweight (\< 1500 g birthweight) children.

    Other: N/A, no intervention, participation in survey

Interventions

  • OtherN/A, no intervention, participation in survey

    A unified questionnaire will be utilized for all participants, irrespective of their group assignment. Participants will be assigned to the BPD or comparison group retrospectively, based on their answers defining the BPD-status. To enhance comprehension, the questionnaire avoids using the term "BPD" wherever feasible and instead employs a more general reference to lung problems.

06

What researchers measure

Primary outcomes

  1. Parental health-related quality of life (HRQoL) assesed by Pediatric Quality of Life Inventory, Family Impact Module (PedsQL FIM)

    To record the parents' HRQoL, the Pediatric Quality of Life Inventory Family Impact Module (PedsQL FIM) is implemented, a validated and widely used instrument designed to measure the impact of pediatric acute and chronic health conditions on parents and the family. It consists of 36 items across six parental dimensions (physical, emotional, social, and cognitive functioning, communication, and worry), as well as family daily activities and relationships. It is validated in all official languages of the seven participating countries (English, French, German, Italian, Dutch, Spanish) and allows the calculation of a sum score.

    Time frame: 09/2025 - 02/2026

Secondary outcomes

  1. Participant characteristics assesed by self developed online questionnaire

    Inclusion/exclusion criteria, Baseline characteristics, socio-demographic characteristics of parent/caregiver, child, and the family situation

    Time frame: 09/2025 - 02/2026

  2. Medical Situation of the child assesed by self developed online questionnaire (parent report)

    The section assesses the child's overall health, daily functioning, school attendance, and involvement of medical specialists. It covers emotional, cognitive, and behavioral issues (potentially linked to BPD), respiratory health (symptoms, infections, treatments, support), and feeding difficulties. It also records comorbidities and developmental impairments, and includes questions on RSV prevention and infection history.

    Time frame: 09/2025 - 02/2026

  3. Economic burden on families (Quantitative and qualitative) assesed by adapted version of the Family Economic Impact Inventory (Domain Family Finances)

    The Family Finances section captures family costs related to caring for a child with health conditions, including direct and broader economic impacts such as financial burden, work productivity loss, and healthcare utilization.

    Time frame: 09/2025 - 02/2026

  4. Health Literacy (Quantitative) assesed by self-developed online questionnaire

    Disease awareness and awareness of consequences

    Time frame: 09/2025 - 02/2026

  5. Support Structures (Quantitative and qualitative) assesed by self developed online questionnaire

    Time frame: 09/2025 - 02/2026

07

Study locations

1 of 1 sites recruiting
  • Global Foundation for the Care of Newborn Infants (GFCNI)
    München, Bavaria 81379, Germany
    Recruiting
08

References and documents

Publications

  • Trautmannsberger I, Wydrin V, Duzenli A, Breunig L, Mader S, Tischer C, Feiler J. BronQ Family: assessing the long-term impact of Bronchopulmonary Dysplasia on affected families' health-related quality of life - protocol of a multi-country study. BMJ Paediatr Open. 2026 Apr 30;10(1):e004252. doi: 10.1136/bmjpo-2025-004252. PubMed 42062067 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Feb 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 21, 2025
StartActual
Sep 16, 2025
Primary completionEst.
Feb 2026
CompletionEst.
Jan 2027
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07134387
Lead sponsor
Global Foundation for the Care of Newborn Infants
Collaborators
European Society for Paediatric Research (ESPR), Union of European Neonatal and Perinatal Societies (UENPS), European Respiratory Society (ERS)
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Sep 16, 2025
Primary completion
Feb 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 21, 2025

Study contacts

Christina Tischer, Dr
Contact
research@efcni.org
+49 (0)89 / 89083260
Julia Feiler, Dr
Contact
Julia.feiler@gfcni.org
Julia Feiler, Dr
principal investigator · Global Foundation for the Care of Newborn Infants (GFCNI)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion